Chisari Giuseppe, Chisari Eleonora M, Borzi Antonio M, Chisari Clara G
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.
Department of Education, University of Catania, Catania, Italy.
Curr Clin Pharmacol. 2017;12(2):99-105. doi: 10.2174/1574884712666170704145046.
Aging and oxidative stress seem to play a key role in the onset and progression of ocular surface diseases. Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface in which symptoms may interfere with the ability to work and carry out daily functions.
This clinical trial was a pilot study to evaluate the effects of supplementation with mixture (Saccharomyces boulardii MUCL 53837 and Enterococcus faecium LMG S-28935) on the tear film. Following the run-in period subjects were randomized in two groups: group A (n.30 subjects) and group B (n.30 subjects). Group A (control) treated only with substitute tear and group B treated with substitute tear + mixture (probiotic).
The data obtained in the two study groups A and B were, respectively the following: Schirmer I: 9.2±0.2 vs. 12.8±0.4 (p< 0.001); Schirmer II: 3.6±0.1 vs. 4.6±0.2 (p<0.001); BUT 3.8±0.3 vs. 6.2±0.2 (p<0.001). Culture test showed initial bacterial growth in group "A" (placebo) 27 out of 60 samples tested, corresponding to 45.0% and "B" after treatment (probiotic) was found positive culture whit growth of bacteria in 18 tests equal to 30.0%. The total numbers of isolations of aerobic and anaerobic bacteria found group A and B after treatment. A reduction of 23 to 16 strains of aerobic and anaerobic isolates from 13 to 7 has been found.
The administration of probiotics strains was effective in reducing DES. In light of these results, we have identified our probiotic (Saccharomyces boulardii MUCL 53837 and Enterococcus faecium LMG S-28935) activity integration with the action of tear substitutes, along with standardization of clinical parameters of the tear film and microbiological activity in restoring of the microbiota ocular surface subject with DES.
衰老和氧化应激似乎在眼表疾病的发生和发展中起关键作用。干眼症（DES）是一种涉及泪液和眼表的多因素疾病，其症状可能会干扰工作能力和日常功能的执行。
本临床试验是一项试点研究，旨在评估补充混合物（布拉氏酵母菌MUCL 53837和粪肠球菌LMG S - 28935）对泪膜的影响。在导入期后，受试者被随机分为两组：A组（30名受试者）和B组（30名受试者）。A组（对照组）仅用替代泪液治疗，B组用替代泪液 + 混合物（益生菌）治疗。
在两个研究组A和B中获得的数据分别如下：泪液分泌试验I：9.2±0.2对12.8±0.4（p < 0.001）；泪液分泌试验II：3.6±0.1对4.6±0.2（p < 0.001）；泪膜破裂时间3.8±0.3对6.2±0.2（p < 0.001）。培养试验显示，在“A”组（安慰剂组）测试的60个样本中有27个出现初始细菌生长，占45.0%，而“B”组在治疗后（益生菌组）有18次培养试验发现细菌生长呈阳性，占30.0%。发现了治疗后A组和B组需氧菌和厌氧菌的分离总数。需氧菌和厌氧菌分离株数量从A组的23株减少到16株，从B组的13株减少到7株。
益生菌菌株的施用对减轻干眼症有效。鉴于这些结果，我们确定了我们的益生菌（布拉氏酵母菌MUCL 53837和粪肠球菌LMG S - 28935）与泪液替代物作用的活性整合，以及泪膜临床参数的标准化和微生物活性在恢复干眼症受试者眼表微生物群方面的作用。
